19 June 2017

Sandoz weighs into European rituximab biosimilar market

Sandoz has gained European approval for its biosimilar version of Roche’s blockbuster MabThera/Rituxan (rituximab) to be called Rixathon. The approval comes hot on the heels of Celltrion’s Truxima, which was the first biosimilar version of the drug to gain EU clearance in February this year. Roche’s MabThera/Rituxan global revenues for 2016 were 7.3 billion swiss francs ($7.51bn), with 1.87bn coming from Europe. Source: Pharmaphorum 19/6/2017

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).